Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q93063
UPID:
EXT2_HUMAN
Alternative names:
Glucuronosyl-N-acetylglucosaminyl-proteoglycan/N-acetylglucosaminyl-proteoglycan 4-alpha-N-acetylglucosaminyltransferase; Multiple exostoses protein 2; Putative tumor suppressor protein EXT2
Alternative UPACC:
Q93063; B2R5Z6; C9JU51; J3KPT2; O15288
Background:
Exostosin-2, also known as Multiple exostoses protein 2, plays a crucial role in the biosynthesis of heparan-sulfate. This protein, in collaboration with EXT1, forms a complex that significantly enhances glycosyltransferase activity, pivotal for cell growth and development. It is also implicated in tumor suppression and is essential for the exosomal release of key proteins.
Therapeutic significance:
Exostosin-2 is linked to Hereditary multiple exostoses 2, Potocki-Shaffer syndrome, and Seizures, scoliosis, and macrocephaly/microcephaly syndrome. These associations highlight its potential as a target for therapeutic intervention in bone disorders and neurological conditions. Understanding the role of Exostosin-2 could open doors to potential therapeutic strategies.